<DOC>
	<DOCNO>NCT02919800</DOCNO>
	<brief_summary>A Phase 1 , randomize , single-blind , placebo-controlled , single dose , dose-escalation study ass safety , pharmacokinetic pharmacodynamic profile subcutaneous administration long-acting recombinant factor VIIa ( MOD-5014 ) healthy adult male .</brief_summary>
	<brief_title>A Single-dose , Dose-escalation Study Long-acting MOD-5014 Healthy Adult Male</brief_title>
	<detailed_description>This single-dose , randomize , single-blind , placebo-controlled , dose-escalating study . The study include four escalate dose group , eight subject dose group . Subjects randomized 3:1 ratio receive single SC injection MOD-5014 ( n=6 ) placebo ( n=2 ) , follow 30 day . The initial MOD-5014 dose group receive 100 µg/kg follow single dos 200 , 400 600 µg/kg administer subsequent subject cohort . The decision proceed high dose level make Data Safety Monitoring Board ( DSMB ) review relevant safety data ( include adverse event , clinical laboratory vital sign ) , collect include 7 day last subject previous dose group dose . Common Terminology Criteria Adverse Events ( CTCAE ) guideline use determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) . Dose escalation permit prior dose well tolerate , safety tolerability concern raise investigator , sponsor , medical monitor DSMB 7 day post-dosing .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>1 . Men , 1850 year age , inclusive , screen visit . 2 . Subjects must provide write informed consent prior participate study . 3 . Considered healthy base medical history , physical examination clinical laboratory result . 4 . Body Mass Index ( BMI ) 19.030.0 kg/m2 total body weight &gt; 50 Kg . 5 . Fertile men must agree use barrier contraceptive ( condom ) 30 day postdosing restricted donate sperm 30 day dose . Subjects vasectomy perform 6 month prior treatment also acceptable . 6 . Supine blood pressure heart rate within normal limit ( systolic 90140 mmHg ; diastolic 5090 mmHg , heart rate 45100 beat per minute ) . No evidence orthostatic hypotension . 7 . Triglyceride ≤ 200 mg/dl 8 . ECG clinically significant abnormality record Screening visit dose day ( drug administration ) : PR interval within 120 210 m , QRS interval &lt; 120 m , QTc interval 450 ms. 9 . Negative human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C serology test screen . 10 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . 11 . Nonsmoking use tobacco nicotine product declaration period least 6 month prior screening period . 1 . Family history blood clot . 2 . Have , within one month prior study drug administration , major surgical procedure ( e.g . orthopedic , abdominal ) elective surgery plan within study period . 3 . Any history arterial and/or venous thromboembolic event ( myocardial infarction , ischemic stroke , transient ischemic attack , deep venous thrombosis pulmonary embolism ) . 4 . History current drug/alcohol abuse ( exclude use medicinal cannabis pain management ) . History regular alcohol consumption exceed 14 drinks/week men ( 1 drink = 5 ounce [ 150 mL ] wine 12 ounce [ 360 mL ] beer 1.5 ounce [ 45 mL ] hard liquor ) within 6 month screen . Positive urine drug abuse ( DoA ) screen admission . Positive breath alcohol test admission . 5 . Known allergy drug . Known allergy hypersensitivity test compound material contraindication test product . 6 . Use prescription overthecounter ( OTC ) medication , include vitamin herbal dietary supplement within 14 day prior dose . Paracetamol symptomatic relief pain allow 24 hour prior study drug administration . 7 . Subjects receive vaccine within 4 week prior study drug administration . 8 . Participation another clinical trial within 30 day .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>